Provided by Tiger Trade Technology Pte. Ltd.

Oculis

13.18
+0.09500.73%
Post-market: 13.250.0700+0.53%19:30 EDT
Volume:150.39K
Turnover:1.97M
Market Cap:813.63M
PE:-7.68
High:13.25
Open:13.10
Low:12.87
Close:13.09
52wk High:34.48
52wk Low:10.52
Shares:61.73M
Float Shares:53.44M
Volume Ratio:0.86
T/O Rate:0.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7151
EPS(LYR):-2.3888
ROE:-43.70%
ROA:-24.95%
PB:2.98
PE(LYR):-5.52

Loading ...

Oculis Holding Is Maintained at Overweight by JP Morgan

Dow Jones
·
Jun 04

Oculis price target lowered to $23 from $42 at JPMorgan

TIPRANKS
·
Jun 03

J.P. Morgan Reaffirms Their Buy Rating on Oculis Holding (OCS)

TIPRANKS
·
Jun 03

Oculis Holding Ag : JP Morgan Cuts Target Price to $23 From $42

THOMSON REUTERS
·
Jun 03

Eoptolink Technology Announces Comprehensive Positioning in Optical Circuit Switch Market

Deep News
·
Jun 02

Oculis Holding (OCS) Gets a Buy from Leerink Partners

TIPRANKS
·
Jun 02

Oculis Holding Is Maintained at Outperform by Baird

Dow Jones
·
Jun 02

Small U.S. Stocks Decrease; Oculis Holding Takes Biggest Hit

Dow Jones
·
Jun 02

Top Premarket Decliners

MT Newswires Live
·
Jun 01

Oculis Holding Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT)

TIPRANKS
·
Jun 01

Oculis price target lowered to $40 from $50 at Stifel

TIPRANKS
·
Jun 01

Oculis Maintained at Buy as Analyst Lowers Price Target to $45, Refocuses on Optic Neuritis Opportunity

TIPRANKS
·
Jun 01

Oculis Holding Ag : Leerink Partners Cuts Target Price to $40 From $50

THOMSON REUTERS
·
Jun 01

Analyst Maintains Buy on Oculis, Sees Upside Driven by Optic Neuropathy and Dry Eye Pipelines Despite OCS-01 Phase 3 Setback

TIPRANKS
·
Jun 01

Stocks to Watch: Oculis, Lisata, Healthy Choice Wellness

Dow Jones
·
May 30

Small U.S. Stocks Close Lower; Oculis Holding Takes Biggest Hit

Dow Jones
·
May 30

Oculis Shares Fall After Decision To Not Pursue FDA Approval For Eye Disease Treatment

Dow Jones
·
May 30

Oculis Holding AG Phase 3 Trial of Potential Eye Drops for Diabetic Patients Fails to Primary Endpoint

MT Newswires Live
·
May 30

Oculis reports primary endpoint of DIAMOND Phase 3 trials was not met

TIPRANKS
·
May 30